• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    3/13/26 8:35:24 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email
    false --12-31 0001726711 0001726711 2026-03-10 2026-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 10, 2026

     

    Aditxt, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39336   82-3204328
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2569 Wyandotte St., Suite 101, Mountain View, CA   94043
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 870-1200

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-47(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   ADTX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into Material Definitive Agreement

     

    On March 11, 2026, Aditxt, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with IMAC Holdings, Inc. (“IMAC”) and the several investors listed on the Schedule of Buyers attached to the Agreement (collectively, the “Buyers”) whereby the Buyers sold 100% of their equity interests in Ignite Proteomics, LLC, a Delaware limited liability company (“Ignite”) and formerly a wholly owned subsidiary of IMAC plus $475,000 in cash, for a total consideration of 36,000 shares of the Company’s newly created Series A-2 Convertible Preferred Stock (the “Preferred Shares”). The stated value of the Preferred Shares is $1,000 per share for a total of $36,000,000 in preferred stock. The equity interests of Ignite purchased by the Company under the Agreement represent 100% of the issued and outstanding equity of Ignite.

     

    The Preferred Shares are convertible into shares of Company common stock (“Common Stock”) and have the terms summarized in Item 5.03 of this Current Report on Form 8-K. If, as of the first anniversary of the Closing Date (as defined in the Agreement), the Conversion Price (as defined in the Certificate of Designation for the Preferred Shares) is less than the Market Price (as defined in the Agreement), the Company shall provide each stockholder entitled to vote at the next annual meeting of stockholders of the Company a proxy statement soliciting each such stockholder’s affirmative vote at the stockholder meeting for approval to change the amount of the Conversion Price to such lower number. If the stockholders do not approve changing the Conversion Price, the Company will again recommend approval of the new Conversion Price at each succeeding annual meeting of stockholders until such approval is obtained. 

     

    Item 2.01 Completion of Acquisition or Disposition of Assets

     

    On March 11, 2026, the Company completed the acquisition described in Item 1.01 above. The information set forth in Item 1.01 is hereby incorporated by reference.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

     

    On March 11, 2026, the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with the several buyers listed on the issuance schedule attached thereto (the “Note Buyers”), pursuant to which the Company will issue its 10% original issue discount promissory notes (the “Notes”) for the aggregate principal amount of $3,194,444.44. The aggregate funding amount from all Note Buyers was $2,875,000 at closing.

     

    The Notes bear interest on the outstanding principal balance at 6% per annum and shall adjust to 12% per annum upon an Event of Default (as defined in the Note) so long as such Event of Default remains uncured. The Notes may be prepaid at anytime with no penalty. The Notes mature nine months from the issuance date, and all outstanding principal and accrued interest shall be due on the maturity date.

     

    Events of Default include:

     

    ●Failure to pay principal and interest when due

     

    ●Failure to pay any other amounts owing under the Notes within five business days of when due

     

    ●The Company or any subsidiary commencing bankruptcy or insolvency proceedings

     

      ● The Company or any subsidiary defaulting beyond any applicable grace and cure periods under any mortgage or other debt instrument under which there may be issued, or by which there may be secured or evidenced any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement of the Company or any subsidiary of the Company in an amount exceeding $250,000,

     

      ● The Company’s common stock ceasing to be quoted or listed for trading for five consecutive trading days due to voluntary delisting or failing to comply with applicable listing standards on the principal market where such common stock is traded

     

    ●The Company’s failure to timely file any required periodic reports with the U.S. Securities and Exchange Commission (including any permitted filing extensions)

     

    ●Any representation or warranty of the Company under the Note or the Note Purchase Agreement ceasing to be accurate in any material respect or any material provision of the Note or Note Purchase Agreement ceasing to be in full force and effect

     

    ●The Company using the proceeds from the Notes to purchase or carry margin stock (within the meanings of Regulations T,U and X under the Federal Reserve Board)

     

    ●Any Event of Default occurs in any Note or Transaction Document (as such terms are defined in the Note Purchase agreement) or in any other agreement between the Company and a Note Buyer resulting in the right of a Note Buyer to accelerate the maturity of such indebtedness in an amount in excess of $250,000

     

    ●Failing to perform any material covenant under the Note or the Note Purchase Agreement.

     

    A Note Buyer also has the right to roll all or any portion of a Note into securities issued by the Company in future capital-raising transactions.

     

    -1-

     

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    On March 11, 2026, the Company completed the acquisition described in Item 1.01 above. The information set forth in Item 1.01 is hereby incorporated by reference.

     

    The Preferred Shares were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

     

    Pursuant to the terms of the Agreement, on March 10, 2026, the Company filed the Certificate of Designations with the Delaware Secretary of State designating, 36,000 shares of its authorized and unissued Preferred Shares as Series A-2 Convertible Preferred Shares (the “Preferred Shares”). The Certificate of Designations sets forth the rights, preferences and limitations of the shares of Preferred Shares. Terms not otherwise defined in this item shall have the meanings given in the Certificate of Designations.

     

    The following is a summary of the terms of the Preferred Shares:

     

    Conversion. Pursuant to the Certificate of Designations, which is filed as Exhibit 3.1 to this Current Report on Form 8-K (the “Certificate of Designations”), each Preferred Share is convertible at the option of the holder, into a number of shares of Common Stock determined by dividing the (x) Conversion Amount by (y) the Conversion Price. The Conversion Price is $2.731, subject to adjustment as provided in the Certificate of Designations Conversion Amount means the sum of (A) the Stated Value ($1,000), (B) any Additional Amount and (C) any other amounts owed to such holder.

     

    The Preferred Shares will be convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Shares such that an Investor may not beneficially own more than 9.99% (the “Maximum Percentage”) of the shares of Common Stock that would be issued and outstanding following such conversion.

     

    Ranking. All existing Preferred Shares of the Company as of the date hereof (together with any future Preferred Shares of the Company that the Board designates as senior to the Preferred Shares, collectively, the “Senior Preferred Shares”) shall rank senior to the Preferred Shares. Any Preferred Shares of the Company may be designated by the Board of pari passu rank to the Preferred Shares in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company shall rank pari passu to the Preferred Shares. Any Preferred Shares of the Company may be designated by the Board of junior rank to the Preferred Shares in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company and/or any Common Stock shall rank junior to the Preferred Shares. In the event of the merger or consolidation of the Company with or into another corporation, the Preferred Shares shall maintain its relative rights, powers, designations, privileges and preferences provided for herein and no such merger or consolidation shall result inconsistent therewith.

     

    -2-

     

     

    Redemption. The Company shall have the right at any time to redeem some or all of the Preferred Shares at a price equal to 100% of the Conversion Amount at the time of redemption. Further, upon notice of redemption by the Company to each holder, each holder shall have the right to convert up to 20% of the amount to be redeemed prior to the redemption being completed.

     

    Dividends. Subject to the senior rights of the Senior Preferred Shares, and pari passu with the holders of shares of Parity Stock, from and after the first date of issuance of any Preferred Shares, each holder of a Preferred Share shall be entitled to receive dividends when and as declared by the Board, from time to time, in its sole discretion, which Dividends shall be paid by the Company out of funds legally available therefor, payable, subject to the conditions and other terms hereof, in cash, in securities of the Company or any other entity, or using assets as determined by the Board on the Stated Value of such Preferred Share.

     

    Voting Rights. Notwithstanding anything in the Certificate of Designation to the contrary, the Preferred Shares shall have no voting rights, except as required by applicable law or as expressly provided in the Certificate of Incorporation or this Certificate of Designation and shall not be entitled to any voting rights, other than any vote required by law or the Certificate of Incorporation.

     

    Liquidation. In the event of a Liquidation Event, the Holders shall be entitled to receive in cash out of the assets of the Corporation, whether from capital or from earnings available for distribution to its stockholders, before any amount shall be paid to the holders of any of shares of Junior Stock, but pari passu with any Parity Stock then outstanding, an amount per share of Series A equal to the greater of (A) the Conversion Amount thereof on the date of such payment or (B) the amount per share such Holder would receive if such Holder converted such Series A into Common Stock immediately prior to the date of such payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the Holders and holders of shares of Parity Stock, then each Holder and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of Liquidation Funds payable to such Holder and such holder of Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series A and all holders of shares of Parity Stock. To the extent necessary, the Corporation shall cause such actions to be taken by each of its Subsidiaries so as to enable, to the maximum extent permitted by law, the proceeds of a Liquidation Event to be distributed to the Holders in accordance with the Certificate of Designation. All the preferential amounts to be paid to the Holders pursuant to the Certificate of Designations shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any Liquidation Funds of the Corporation to the holders of shares of Junior Stock in connection with a Liquidation Event.

     

    Purchase Rights. if at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock, then each Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such Holder could have acquired if such Holder had held the number of shares of Common Stock acquirable upon complete conversion of all the Preferred Shares (without taking into account any limitations or restrictions on the convertibility of the Preferred Shares and assuming for such purpose that all the Preferred Shares were converted at the Conversion Price as of the applicable record date) held by such Holder immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.

     

    In addition, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock, the Company shall make appropriate provision to ensure that each Holder will thereafter have the right, at such Holder’s option, to receive upon a conversion of all the Preferred Shares held by such Holder (i) in addition to the shares of Common Stock receivable upon such conversion, such securities or other assets to which such Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by such Holder upon the consummation of such Corporate Event.

     

    Right of First Refusal upon Transfer of Ignite Business and/or Assets. So long as the Collateral Agent (as defined in the Agreement) holds any Preferred Shares, the Company shall not sell or lease (other than to a wholly-owned or to a controlled subsidiary), or dispose of any of the business or assets (other than disposal of assets in the ordinary course of business or the licensing of any such assets) of Ignite (as defined in the Purchase Agreement) whether in a single transaction or a series of related transactions without first offering the Collateral Agent (as defined in the Purchase Agreement and for the benefit of the Holders) a written right of first refusal to purchase such applicable business and/or assets of Ignite, as applicable, for such cash amount (with any non-cash consideration valued at the fair market value thereof as reasonably determined) proposed to be paid by such applicable purchaser. In such event, the Collateral Agent shall have five business days to elect to exercise its Right of First Refusal.

     

    -3-

     

     

    Item 8.01 Other Events

     

    On March 13, 2026, the Company issued a press release announcing completion of the transaction described above in this Current Report on Form 8-K.

     

    A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    As previously disclosed in the Company’s Current Report on Form 8-K filed on December 5, 2025, on December 1, 2025, the Company received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million, minimum market value of listed securities of $35 million, or net income from continuing operations of $500,000 (the “Stockholders’ Equity Requirement”). As previously disclosed, on January 27, 2026, Nasdaq granted the Company an extension through May 15, 2026 to regain compliance with the Stockholders’ Equity Requirement. As a result of the completion of the Ignite transaction described in Item 1.01 above, the Company believes that, as of the date of this Current Report on Form 8-K, it has stockholders’ equity in advance of $2.5 million and has regained compliance with the Stockholders’ Equity Requirement. Nasdaq will continue to monitor the Company’s ongoing compliance with the Stockholders’ Equity Requirement and, if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting. The Company is awaiting Nasdaq’s confirmation that it has regained compliance.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (a) Financial statements of business or funds acquired.

     

    The (i) audited balance sheet of Ignite as of December 31, 2025 and the related audited statement of operations, statement of stockholders’ deficit, and cash flows, for the fiscal year for the period ended December 31, 2025 will be filed by amendment to this Current Report on Form 8-K within the timeframe provided by Item 9.01(a)(3).

     

    (b) Pro forma financial information.

     

    The unaudited pro forma consolidated financial information of the Company giving pro forma effect to the acquisitions of Ignite Proteomics LLC, consisting of (i) unaudited pro forma consolidated statement of financial position as at December 31, 2025, the unaudited pro forma consolidated statement of financial position for the year ended December 31, 2025, and the unaudited consolidated pro forma statement of earnings for the year ended December 31, 2025 will be filed by amendment to this Current Report on Form 8-K within the timeframe provided by Item 9.01(b)(2).
     

    (d) Exhibits.

     

    Exhibit No.   Exhibit
    3.1   Certificate of Designations of Rights and Preferences of Series A-2 Convertible Preferred Stock
         
    10.1   Securities Purchase Agreement dated as of March 11, 2026 by and between the Company, IMac Holdings, Inc. and the Buyers listed on the Schedule of Buyers attached thereto
         
    10.2   Note Purchase Agreement dated as of March 11, 2026 by and between the Company and the several Buyers listed on the issuance schedule attached thereto.
         
    99.1   Press Release dated March 13, 2026
         
    104   Cover Page Interactive Data File (embedded within the XBRL document)

     

    -4-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ADITXT, INC.
         
    Date: March 13, 2026 By: /s/ Amro Albanna
        Amro Albanna
        Chief Executive Officer

     

    -5-

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADTX
    SEC Filings

    View All

    Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/13/26 8:35:24 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/5/26 8:30:35 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Aditxt, Inc. (0001726711) (Filer)

    2/13/26 5:03:05 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dawson James initiated coverage on ADiTx Therapeutics

    Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy

    2/4/21 8:32:09 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the reconvened special meeting held on February 13, 2026, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025877. As a r

    3/5/26 8:30:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

    Aditxt has filed a preliminary proxy statement seeking shareholder approval for employee stock purchase plan, company name change, and other proposals Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today shared its growth vision under the bitXbio™ strategy. bitXbio™ (pronounced "bit-by-bio") is a transformational framework designed to connect public markets, blockchain and Web3, and digital asset treasuries for advancing breakthrough health innovations. The bitXbio™ strategy is intended to scale Aditxt as a social innovation platform representing a global community of shareholders and contributors engaged thr

    11/18/25 8:00:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    10/17/24 1:58:54 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Brady Brian Michael sold $2 worth of shares (1 units at $1.75), decreasing direct ownership by 25% to 3 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    12/19/25 5:00:02 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief M&A Officer Pankovcin Corinne sold $3 worth of shares (1 units at $3.20), closing all direct ownership in the company (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    11/26/25 4:30:18 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Porcelli Christopher Jon claimed no ownership of stock in the company (SEC Form 3)

    3 - Aditxt, Inc. (0001726711) (Issuer)

    10/3/25 8:00:06 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

    -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt --  SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Bioscienc

    8/14/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports Fourth Consecutive Year of Net Sales Growth

    -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

    3/24/25 8:30:00 AM ET
    $ADTX
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADTX
    Leadership Updates

    Live Leadership Updates

    View All

    Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

    6/9/25 8:15:00 AM ET
    $ADTX
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

    Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in

    4/2/25 8:17:20 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

    SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

    2/14/24 2:14:47 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

    SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

    2/6/24 10:06:47 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

    SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

    1/2/24 3:10:18 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care